Document is current

Article History

Received: 3 October 2025

Accepted: 30 October 2025

First Online: 8 December 2025

Declarations

:

: April Armstrong: Research investigator and/or scientific advisor to AbbVie, Almirall, Arcutis, ASLAN, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly, EPI, Incyte, Janssen, LEO Pharma, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sun Pharma, Sanofi, and UCB. Kim A. Papp: Received honoraria and/or grants from AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Therapeutics, Eli Lilly, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte, Johnson & Johnson, Kymab, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis/Genzyme, Sun Pharma, Takeda, Tarsus, UCB, and Zai Lab. Mark Lebwohl: Employee of Mount Sinai; receives research funds from Abbvie, Amgen, Arcutis, Avotres Therapeutics, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB; consultant for Almirall, AltruBio Inc., AnaptysBio, Apogee, Arcutis Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, EPI, Evommune Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. Mark Lebwohl is an Editorial Board member of Dermatology and Therapy . Mark Lebwohl was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Laura J. Savage: Received grant/research support from Johnson and Johnson and Pfizer; consultant for AbbVie, Almirall, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Johnson and Johnson, LEO Pharma, Novartis, and UCB; speaker for AbbVie, Almirall, Amgen, Aspire Pharma, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Galderma, Johnson and Johnson, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, Takeda, and UCB. Keiichi Yamanaka: Grants from AbbVie, Bayer Yakuhin, Eisai, Eli Lilly, Kaken Pharmaceutical, Kyowa Kirin, Maruho, Maruho Takagi Dermatology Foundation, Nihon Pharmaceutical, Nippon Kayaku, Sasaki Chemical, Taiho Pharmaceutical, Torii Pharmaceutical, and Sun Pharma; speaker for AbbVie, Celgene, Daiichi Sankyo, Eisai, Eli Lilly, Janssen, Kaken Pharmaceutical, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi-Tanabe Pharmaceutical, Nippon Kayaku, Nobelpharma, Novartis, Sanofi, Sun Pharma, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB. Diana Elena Vlase: Psoriasis Patient, Volunteer in National Patient Organization, Volunteer in European Group YASJC (Young Advocates with Chronic Skin and Joint Conditions), Workshop Participant (UCB). Rhys Warham: Veramed statistical consultant for UCB. Jérémy Lambert; José M. López Pinto; Krista Wixted: Employees and shareholders of UCB Pharma. Diamant Thaçi: Investigator and/or consultant/advisor for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Galderma, Incyte, Johnson and Johnson, Kyowa Kirin, LEO Pharma, L’Oréal, New Bridge, Novartis, Pfizer, Regeneron, Samsung, Sanofi, Takeda, Target-RWE, UCB, and Vichy; received grants from AbbVie, LEO Pharma and Novartis.

: The BE SURE, BE VIVID, BE READY, and BE BRIGHT studies were conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guidance for Good Clinical Practice. Ethical approvals were obtained from the relevant institutional review boards at participating sites. All patients provided written informed consent in accordance with local requirements. The authors thank the patients, the investigators and their teams who took part in these studies. All the results presented in this article are in aggregate form, and no personally identifiable information was used for these studies.